Welcome to our dedicated page for NYSE news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on NYSE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NYSE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NYSE's position in the market.
Lockheed Martin (NYSE: LMT) signed a seven-year framework agreement with the U.S. Department of War to accelerate PAC-3® MSE interceptor production and delivery.
The deal targets an increase in annual capacity from ~600 to 2,000 PAC-3 MSEs, cites recent production growth (620 delivered in 2025; >60% increase over two years), and uses a collaborative financing model to preserve initial cash neutrality while enabling supplier investment and cost-savings sharing.
An initial contract award is expected after final FY2026 Congressional appropriations.
White Mountains (NYSE: WTM) announced final results of its modified Dutch auction tender offer that expired December 19, 2025. The company accepted 64,064 shares at a final purchase price of $2,050.00 per share, for an aggregate purchase of approximately $131.3 million. The purchased shares represent approximately 2.5% of White Mountains's shares outstanding as of November 19, 2025.
Payment will be made promptly and the company expects to have approximately 2,479,677 common shares outstanding immediately after payment. Shareholders may contact D.F. King & Co. for additional information; dealer managers were BofA Securities and Barclays Capital.
Cars Commerce (NYSE:CARS) announced that on Dec 22, 2025 it granted inducement equity awards to Tobias Hartmann in connection with his hiring as Chief Executive Officer-Designate.
The awards consist of 155,885 performance-based stock units (PSUs) and 233,827 restricted stock units (RSUs), granted under the company's 2025 Inducement Equity Plan and approved by a majority of independent directors.
The RSUs vest ratably over three years; the PSUs vest after a three-year performance period subject to specified stock price targets set by the board. Grants were made relying on the NYSE employment inducement exemption under Rule 303A.08 and are publicly disclosed as required.
Genesco (NYSE: GCO) said its management team will present at the 2026 ICR Conference on Monday, January 12, 2026.
The live webcast is scheduled to begin at 9:30 a.m. Eastern and can be accessed via Genesco's investor relations page at www.genesco.com. The announcement identifies timing and the webcast link for investors.
Cars Commerce (NYSE: CARS) named Tobias Hartmann as Chief Executive Officer and director, effective January 15, 2026. Hartmann will succeed Alex Vetter, who will step down as CEO and board member on that date and serve as an advisor through March 31, 2026 to support the transition. Hartmann brings more than 25 years of experience across B2C and B2B technology, eCommerce and marketplaces, including CEO and chairman roles at Scout24 and senior leadership at HelloFresh and eBay Enterprise carve-outs.
The board described a comprehensive succession process and cited Hartmann’s track record in scaling digital businesses, while Vetter—company leader since 1998 and CEO since 2014—will exit the CEO and board roles to enable the leadership change.
Actinium Pharmaceuticals (NYSE: ATNM) presented preclinical data for ATNM-400, an Actinium-225 antibody radioconjugate, at SABCS 2025 showing potent anti-tumor activity across HR+, TNBC, and tamoxifen- and trastuzumab-resistant breast cancer models.
Key findings include significant tumor-growth inhibition in HR+ and TNBC models, increased target expression and enhanced cytotoxicity in treatment-resistant models, combination-induced tumor regression in a trastuzumab-resistant model, sustained tumor uptake through 144 hours, and rapid clearance from normal organs suggesting a differentiated tolerability profile.
Lockheed Martin (NYSE:LMT) is nearing completion of a new 88,000-square-foot Missile Assembly Building-5 (MAB-5) in Courtland, Alabama, with on-track completion by early 2026 and a formal grand opening to follow.
MAB-5 is purpose-built to produce the Next Generation Interceptor (NGI) for the Missile Defense Agency, emphasizing speed, producibility and repeatability using digital engineering tools including digital twins, model-based systems engineering and virtual testing. The Courtland site employs nearly 500 people, with about 100 employees projected for MAB-5 when fully operational; adjacent Troy facilities will support integration and large-scale manufacturing.
Alexander & Baldwin (NYSE: ALEX) agreed to be taken private in a definitive merger for $21.20 per share cash, implying an enterprise value of approximately $2.3 billion including outstanding debt. The price represents a 40.0% premium to the December 8, 2025 closing price. The transaction, unanimously approved by the board, is expected to close in Q1 2026 subject to customary conditions and shareholder approval. A fourth-quarter 2025 dividend of $0.35 per share was declared, payable January 8, 2026; the merger consideration will be reduced to reflect this dividend. The Investor Group plans to keep A&B's Honolulu headquarters, retain local leadership, and invest over $100 million across the portfolio.
Adient (NYSE:ADNT) completed acquisition of a 49% equity stake in SCI (Zhangjiakou) Co., Ltd. and formed a strategic joint venture on Dec. 8, 2025.
The JV will develop and manufacture automotive seating solutions for the China market with a focus on serving key Chinese OEMs. The partnership combines Adient's global technology with SCI's local insights to accelerate development and mass production, expand market share, and strengthen Adient's local footprint in China.
Actinium Pharmaceuticals (NYSE: ATNM) will present preclinical data for ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, showing potent anti-tumor activity in triple-negative breast cancer (TNBC) and efficacy in models resistant to tamoxifen and trastuzumab. Data include tumor growth inhibition exceeding 100% at higher doses, elevated target expression in resistant lines, combination activity with standard agents, and a favorable tolerability profile in xenograft models. The program also showed activity in metastatic castrate-resistant prostate cancer and non-small cell lung cancer. The presentation is scheduled for December 11, 2025 at 5:00 PM CT at the San Antonio Breast Cancer Symposium.
